Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13327624 | 0.76 | — | — | |
| SCHEMBL6059815 | 0.76 | — | — | |
| SCHEMBL16904971 | 0.76 | — | — | |
| SCHEMBL16475536 | 0.76 | ALDH1A1 (0.36) | SMN1; SMN2ALDH1A1LMNAUSP2MAPT | |
| SCHEMBL12183868 | 0.72 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL7992810 | 0.71 | LMNA (0.40) | SMN1; SMN2ALDH1A1LMNATSHRCYP3A4 | |
| SCHEMBL24780441 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL30856748 | 0.68 | SMN1; SMN2 (0.33) | SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL5763756 | 0.68 | LMNA (0.38) | SMN1; SMN2ALDH1A1LMNAUSP2MAPT | |
| SCHEMBL31069713 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180072696-A1 | SUBSTITUTED 3-HYDROXY-DELTA-LACTONES FROM EPOXIDES | NATIONAL SCIENCE FOUNDATION | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072696-A1 | SUBSTITUTED 3-HYDROXY-DELTA-LACTONES FROM EPOXIDES | EBP, CYP8B1, HSD3B2 | SMN1; SMN2 4636/4885ALDH1A1 319/4885LMNA 734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.